立体定向体部放射治疗结直肠癌肝转移。
Stereotactic body radiation therapy for colorectal liver metastases.
机构信息
Division of Surgical Oncology, Erasmus University MC, Daniel den Hoed Cancer Centre, The Netherlands.
出版信息
Br J Surg. 2010 Mar;97(3):377-82. doi: 10.1002/bjs.6895.
BACKGROUND
Stereotactic body radiation therapy (SBRT) is a treatment option for colorectal liver metastases. Local control, patient survival and toxicity were assessed in an experience of SBRT for colorectal liver metastases.
METHODS
SBRT was delivered with curative intent to 20 consecutively treated patients with colorectal hepatic metastases who were candidates for neither resection nor radiofrequency ablation (RFA). The median number of metastases was 1 (range 1-3) and median size was 2.3 (range 0.7-6.2) cm. Toxicity was scored according to the Common Toxicity Criteria version 3.0. Local control rates were derived on tumour-based analysis.
RESULTS
Median follow-up was 26 (range 6-57) months. Local failure was observed in nine of 31 lesions after a median interval of 22 (range 12-52) months. Actuarial 2-year local control and survival rates were 74 and 83 per cent respectively. Hepatic toxicity grade 2 or less was reported in 18 patients. Two patients had an episode of hepatic toxicity grade 3.
CONCLUSION
SBRT is a treatment option for patients with colorectal liver metastases who are not candidates for resection or RFA.
背景
立体定向体部放射治疗（SBRT）是结直肠癌肝转移的一种治疗选择。本文评估了 SBRT 治疗结直肠癌肝转移的局部控制、患者生存和毒性情况。
方法
对 20 例连续接受治疗的结直肠肝转移患者进行了 SBRT 治疗，这些患者既不适合手术切除，也不适合射频消融（RFA）。转移灶的中位数数量为 1 个（范围 1-3 个），中位数大小为 2.3cm（范围 0.7-6.2cm）。毒性根据通用毒性标准 3.0 进行评分。根据肿瘤分析得出局部控制率。
结果
中位随访时间为 26 个月（范围 6-57 个月）。22 个月（范围 12-52 个月）后，31 个病灶中有 9 个发生局部失败。2 年局部控制率和生存率分别为 74%和 83%。18 例患者出现 2 级或以下的肝毒性。2 例患者出现 3 级肝毒性。
结论
SBRT 是不适合手术切除或 RFA 的结直肠癌肝转移患者的一种治疗选择。
Zotero 插件